Myo-Inositol in the Treatment of Teenagers Affected by PCOS

Table 1

Anthropometric, endocrine, and metabolic parameters of the patients in treatment groups.

Parameter; M ± SD	Yarina		Inofolic		Yarina + inofolic
	Group I		Group II		Group III
	Baseline	After 3 months	Baseline	After 3 months	Baseline	After 3 months
BMI kg/m^2	22.74 ± 3.75	23.03 ± 3.6	22.3 ± 3.08	21.9 ± 2.5	22.24 ± 3.26	21.99 ± 2.57
Weight kg	61.1 ± 9.92	61.9 ± 9.47	58.6 ± 9.3	57.4 ± 7.6	58.95 ± 9.6	58.05 ± 7.6
PRL ng/ml	11.70 ± 5.11	12.01 ± 4.5	12.98 ± 5.75	12.5 ± 5.32	13.39 ± 4.5	13.03 ± 4.35
LH IU/I	10.42 ± 3.9	8.01 ± 2.9	9.11 ± 5.7	7.56 ± 4.5	13.1 ± 5.58	8.42 ± 3.7
DHEA-S µg/ml	2.03 ± 0.7	1.82 ± 0.46	2.09 ± 0.50	1.89 ± 0.59	2.3 ± 0.67	1.9 ± 0.38
TT ng/ml	0.72 ± 0.25	0.58 ± 0.57	0.73 ± 0.25	0.73 ± 0.46	0.70 ± 0.23	0.51 ± 0.16
FT pg/ml	4.26 ± 2.46	2.74 ± 1.16	3.82 ± 2.01	2.98 ± 0.94	3.42 ± 2.16	2.12 ± 0.8
FAI	7.13 ± 3.8	3.8 ± 2.6	6.7 ± 5.7	5.99 ± 5.24	8.1 ± 5.5	2.94 ± 1.04
SHBG nmol/l	45.03 ± 24.39	55.42 ± 25.7	53.7 ± 27.4	56.29 ± 24.3	47.4 ± 29.2	65.01 ± 22.5
Glucose mmol/l	4.61 ± 0.74	4.36 ± 0.53	4.64 ± 0.65	4.39 ± 0.56	4.64 ± 0.72	4.42 ± 0.52
C-peptide ng/ml	1.6 ± 0.7	1.53 ± 0.34	1.92 ± 0.7	1.82 ± 0.34	1.52 ± 0.7	1.22 ± 0.57
Insulin µIU/ml	8.07 ± 5.24	8.12 ± 4.3	8.5 ± 6.7	5.2 ± 3.04	8.67 ± 4.7	6.67 ± 2.79
HOMA-IR	1.59 ± 1.07	1.57 ± 0.87	1.81 ± 1.38	1.03 ± 0.64	1.73 ± 1.0	1.3 ± 0.56
AMH ng/ml	11.72 ± 5.8	10.26 ± 4.6	11.5 ± 5.8	12.6 ± 6.25	12.01 ± 5.6	10.4 ± 4.7

Comparison of the data at baseline and after treatment within the groups. ; .